Granted Patent
B2
US 8,679,489 · App. 13/762,453 · Granted Mar 25, 2014
Inhibiting cell migration
Assignee:
XBiotech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors.
Claims (2)
1. A method of inhibiting migration of a cell through a basement membrane matrix, the method comprising the step of adding a purified monoclonal antibody (mAb) that specifically binds to human interleukin-1alpha (IL-1α) to a mixture comprising the basement membrane matrix and the cell.
2. The method of claim 1 , wherein the purified mAb is a human IgG1 mAb comprising a heavy chain covalently joined to a light chain.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 10, 2020
From: XBIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 051769/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 8, 2013
From: SIMARD, JOHN
To: XBIOTECH, INC.
Reel/Frame 029779/0058 →
Continuity (6)
Provisional Application
61057586
· May 30, 2008
Provisional Application
61121391
· Dec 10, 2008
Provisional Application
61178350
· May 14, 2009